Estimaciones de analistas de Wall Street para Precigen, Inc. (PGEN): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $0.09 | ||
| 2026-08-04 | $0.05 | $-0.01 | +514.3% |
| 2026-05-13 | $-0.02 | $-0.03 | +33.3% |
| 2026-03-25 | $-0.07 | $-0.10 | +33.6% |
| 2025-11-13 | $-1.06 | $-0.08 | -1225.0% |
| 2025-08-12 | $-0.11 | $-0.09 | -26.9% |
| 2025-05-14 | $-0.18 | $-0.08 | -125.0% |
| 2025-03-19 | $-0.04 | $-0.06 | +33.3% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $190.9M | $231.0M | $160.6M | $32.0M | $32.0M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M |
| Coste de Ventas | $61.6M | $62.8M | $63.3M | $5.4M | $44.8M | $53.7M | $6.3M | $6.1M | $4.3M | $6.1M |
| Beneficio Bruto | $129.3M | $168.2M | $97.3M | $26.6M | -$12.8M | -$39.4M | $20.6M | $106000 | -$342000 | $3.6M |
| I+D | $112.1M | $143.2M | $404.6M | $39.4M | $39.4M | $47.9M | $47.2M | $48.6M | $53.1M | $40.1M |
| Generales y Administrativos | $142.3M | $146.1M | $137.8M | $72.7M | 0 | 0 | $48.0M | $40.4M | $41.3M | $70.1M |
| Gastos Operativos | $254.5M | $289.3M | $542.4M | $112.9M | $73.5M | $52.5M | $96.3M | $99.9M | $134.7M | $110.2M |
| Beneficio Operativo | -$125.2M | -$137.9M | -$505.6M | -$86.3M | -$86.3M | -$91.9M | -$75.7M | -$99.8M | -$135.0M | -$106.6M |
| EBITDA | -$168.7M | -$97.9M | -$349.1M | -$68.8M | -$68.0M | -$77.6M | -$62.4M | -$89.2M | -$123.5M | -$243.6M |
| Gastos por Intereses | $861000 | $611000 | $8.5M | $18.2M | $18.4M | $18.8M | $6.8M | $468000 | $6000 | $3.9M |
| Beneficio Antes de Impuestos | -$194.2M | -$129.7M | -$536.2M | -$104.5M | -$104.5M | -$111.0M | -$80.0M | -$96.4M | -$128.0M | -$250.6M |
| Impuestos | -$3.9M | -$2.9M | -$21.5M | -$82000 | -$82000 | -$160000 | -$189000 | -$458000 | -$1.8M | $3000 |
| Beneficio Neto | -$186.6M | -$117.0M | -$509.3M | -$170.5M | -$170.5M | -$92.2M | $28.3M | -$95.9M | -$126.2M | -$250.6M |
| BPA | $-1.58 | $-0.98 | $-3.93 | $-1.35 | $-1.02 | $-0.47 | $-0.33 | $-0.39 | $-0.47 | $-1.41 |
| BPA Diluido | $-1.58 | $-0.98 | $-3.93 | $-1.35 | $-1.02 | $-0.47 | $-0.40 | $-0.39 | $-0.47 | $-1.41 |
| Acciones en Circulación (Diluidas) | $118.0M | $120.0M | $129.5M | $154.1M | $167.1M | $197.8M | $200.4M | $244.5M | $267.7M | $304.7M |
Precio
| Precio | $7.43 |
| Capitalización | $2.7B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AMLX · DNTH · ELVN · IMTX · NKTR · ORIC · RLAY
Explorar sector: Healthcare · Biotechnology
Más secciones de PGEN: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones